Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light therapy study sheds light on immune changes in transplant complication

NCT ID NCT03438643

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how extracorporeal photopheresis (ECP) — a treatment that uses light to modify a patient's own blood cells — affects the immune system in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Only 8 people were enrolled before the study was stopped early. The goal was to understand why ECP helps some patients, not to test a cure or new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

8 people

The number who actually took part.

Started

May 2018

Finished

Dec 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated with ECP and corticosteroid as first-line treatment for cGVHD.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥18 years who had a first allo-CSH for hematological pathology * Body weight ≥ 40 kg. * Confirmed diagnosis of inaugural cGVHD requiring systemic treatment. * Any source of hematopoietic stem cells is allowed. * All conditioning treatments are allowed. * Patient validated by the local investigator as eligible for treatment with ECP according to the criteria of the investigating centers * Patient treated according to the study plan with a ECP in 2 steps * Patient having signed informed consent. * Prophylaxis of GVH maintained during the onset of cGVHD is accepted. * Effective contraception for men and women of childbearing age. Exclusion Criteria: * cGVHD ≥ 2nd line of treatment * Exclusive pulmonary cGVHD * cGVHD before J100 * cGVHD occurring after Donor Lymphocyte Injection (DLI) * Overlaps syndrome aGVHD-cGVHD * Late aGVHD * Relapsed patient or progressive disease * Non-controlled infection * Second Allograft * Leukopenia \<0.5G / l at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic graft versus host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extracorporeal photopheresis Graft versus host disease

Contacts and locations

Locations

  • Hôpital Claude Huriez, CHU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.